← All trials
NCT02928965
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2013
- Primary completion
- May 1, 2016
- Completion date
- May 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 207
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of ManchesterLead sponsor
- University of EdinburghCollaborator
- University of CambridgeCollaborator
- University of BirminghamCollaborator
- NHS LothianCollaborator
- NHS FifeCollaborator
- University of ManchesterOverall official - principal investigator
- University of ManchesterReponsible party - principal investigator
- University of LondonCollaborator
- West London Mental Health NHS TrustCollaborator
- North East London Foundation TrustCollaborator
- Camden and Islington NHS Foundation TrustCollaborator
- South London and Maudsley NHS Foundation TrustCollaborator
- NHS BordersCollaborator
- University of ManchesterCollaborator
- Salford Royal Foundation NHS TrustCollaborator
- Lancashire Teaching Hospitals NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.